Senol G, Erbaycu A, Ozsöz A
Department of Microbiology, Izmir Chest Diseases and Surgery Research Hospital, Gaziler St. 331, 35110 Izmir, Turkey.
J Chemother. 2005 Aug;17(4):380-4. doi: 10.1179/joc.2005.17.4.380.
Rifabutin is a spiro-piperidyl-rifamycin derived from rifamycin-S. This study was planned to determine the minimal inhibitory concentrations (MICs) of rifabutin and rifampicin against Mycobacterium tuberculosis strains and to investigate cross resistance between two drugs. The agar dilution method was performed for detection of MICs of rifabutin and rifampicin for 112 M. tuberculosis strains obtained from patients with active pulmonary tuberculosis. Cross resistance between rifampicin and rifabutin was detected in 73.1%. Rifabutin MICs for rifampicin resistant strains were three- to four-fold higher than rifabutin-susceptible and/or -resistant strains' MIC values for rifampicin. Despite having 73% cross-resistance with rifampicin in M. tuberculosis isolates, it was concluded that rifabutin might be a valid component of combination therapy in rifampicin resistant tuberculosis cases when the isolate is tested and detected susceptible to rifabutin.
利福布汀是一种从利福霉素-S衍生而来的螺环哌啶基利福霉素。本研究旨在确定利福布汀和利福平对结核分枝杆菌菌株的最低抑菌浓度(MIC),并研究两种药物之间的交叉耐药性。采用琼脂稀释法检测了从活动性肺结核患者中分离出的112株结核分枝杆菌对利福布汀和利福平的MIC。利福平和利福布汀之间的交叉耐药率为73.1%。利福布汀对利福平耐药菌株的MIC值比利福布汀敏感和/或耐药菌株对利福平的MIC值高3至4倍。尽管在结核分枝杆菌分离株中利福布汀与利福平有73%的交叉耐药性,但得出的结论是,当分离株经检测对利福布汀敏感时,利福布汀可能是耐利福平结核病联合治疗的有效组成部分。